Abstract
The tumor marker for hepatocellular carcinoma, alpha-fetoprotein (AFP), has been utilized in association with ultrasound and other imaging methods (HCC). Its utility is constrained by low sensitivity and specificity, as well as differences between the various measurement methods. Also, depending on the patient's characteristics and the used AFP cut-off values, its accuracy fluctuates. Des-gamma-carboxyprothrombin, a new biomarker, was combined with AFP to significantly increase its ability to identify HCC. Elevated AFP levels are usually seen in patients with acute and chronic liver diseases, as well as cirrhosis, and could indicate the severity of hepatic damage and subsequent regeneration. AFP increases can also result from hereditary conditions and other non-hepatic diseases.ase can also result from hereditary conditions and other non-hepatic diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
